Background:  FLVCR is responsible for the exportation of cytoplasmic heme groups. It is believed that it may protect developing erythroid cells from heme toxicity. Expression of FLVCR in cells will cause susceptibility to FeLV-C (Feline leukemia virus subgroup C) in vitro. FLVCR is found in all hematopoietic tissues, including peripheral blood lymphocytes and fetal liver, and some expression is found in pancreas and kidney. It is down-regulated in haemopoietic progenitor cells undergoing differentiation and hemoglobinization. Heme transporter that exports cytoplasmic heme. It can also export coproporphyrin and protoporphyrin IX, which are both intermediate products in the heme biosynthetic pathway. Does not export bilirubin. Heme export depends on the presence of HPX and may be required to protect developing erythroid cells from heme toxicity. Heme export also provides protection from heme or ferrous iron toxicities in liver and brain. Causes susceptibility to FeLV-C in vitro.

Description: Rabbit polyclonal to FLVCR

Immunogen: KLH conjugated synthetic peptide derived from FLVCR

Specificity:  ·Reacts with Human, Mouse, Cat and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 60 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.